文献速递炎症性肠病消化内镜

临床试验中肠道超声评分标准化:克罗恩病管腔病变的专家共识

Standardisation of intestinal ultrasound scoring in clinical trials for luminal Crohn's disease.
PubMed 文献 · Aliment Pharmacol Ther · 2021-02-28

国际专家组采用改良RAND/UCLA方法对120条陈述进行适宜性评分,两轮投票后91条达成适宜共识。组认为肠壁厚度、血管分布、分层及肠系膜炎性脂肪是适宜的疾病活动度指标,但现有IUS活动指数用于临床试验尚不确定;IUS可用于结肠镜无法充分评估病变时的患者筛选及排除并发症,缓解终点可包括肠壁厚度和血管分布(联合或不联合肠系膜炎性脂肪)。

要点

  • 肠壁厚度、血管分布、分层和肠系膜炎性脂肪是适宜的疾病活动度指标
  • 现有IUS疾病活动指数用于克罗恩病临床试验的适宜性尚不确定
  • IUS可用于结肠镜无法充分评估病变时的患者筛选及排除并发症

核心结论

  • 专家组确定了克罗恩病临床试验中肠道超声的适宜组件指标和应用场景。
  • 现有IUS疾病活动指数用于临床试验的适宜性尚不确定,需开发并验证新的指数。

研究设计与样本

  • 国际专家小组由15名成人和儿童胃肠病学家及3名放射学家组成,采用改良RAND/UCLA方法对120条陈述进行适宜性评分。
  • 评分采用1-9分制,中位数1至≤3.5为不适宜,>3.5至<6.5为不确定,≥6.5至9为适宜。
  • 经过两轮投票,91条陈述被评为适宜且达成一致。

主要发现

  • 被认为是疾病活动度适宜指标的項目包括肠壁厚度、血管分布、分层和肠系膜炎性脂肪。
  • 现有IUS疾病活动指数用于克罗恩病临床试验的适宜性存在不确定性。
  • IUS的适宜试验应用包括:当病变肠段无法通过回结肠镜充分评估时用于患者招募资格筛选,以及筛查排除性并发症。
  • 在结局评估中,缓解终点包括肠壁厚度和血管分布,联合或不联合肠系膜炎性脂肪均被认为是适宜的。

关键数值与推荐

  • 120条陈述中91条被评为适宜(中位数≥6.5)且达成一致。
  • 适宜疾病活动度指标:肠壁厚度、血管分布、分层、肠系膜炎性脂肪。
  • 适宜缓解终点:肠壁厚度和血管分布,联合或不联合肠系膜炎性脂肪。

临床怎么用

  • 在克罗恩病临床试验中,可采用肠壁厚度、血管分布、分层和肠系膜炎性脂肪评估疾病活动度。
  • 当回结肠镜无法充分评估病变肠段时,可用IUS进行患者筛选。
  • IUS可用于筛查排除性并发症。
  • 缓解终点评估可采用肠壁厚度和血管分布,联合或不联合肠系膜炎性脂肪。

局限性

  • 现有IUS疾病活动指数用于临床试验的适宜性尚不确定。
  • 需要实证证据以及IUS疾病活动指数的开发和验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Intestinal ultrasound (IUS) is a valuable tool for assessment of Crohn's disease (CD). However, there is no widely accepted luminal disease activity index. AIMS: To identify appropriate IUS protocols, indices, items, and scoring methods for measurement of luminal CD activity and integration of IUS in CD clinical trials. METHODS: An expert international panel of adult and paediatric gastroenterologists (n = 15) and radiologists (n = 3) rated the appropriateness of 120 statements derived from literature review and expert opinion (scale of 1-9) using modified RAND/UCLA methodology. Median panel scores of 1 to ≤3.5, >3.5 to <6.5 and ≥6.5 to 9 were considered inappropriate, uncertain and appropriate ratings respectively. The statement list and survey results were discussed prior to voting. RESULTS: A total of 91 statements were rated appropriate with agreement after two rounds of voting. Items considered appropriate measures of disease activity were bowel wall thickness (BWT), vascularity, stratification and mesenteric inflammatory fat. There was uncertainty if any of the existing IUS disease activity indices were appropriate for use in CD clinical trials. Appropriate trial applications for IUS included patient recruitment qualification when diseased segments cannot be adequately assessed by ileocolonoscopy and screening for exclusionary complications. At outcome assessment, remission endpoints including BWT and vascularity, with or without mesenteric inflammatory fat, were considered appropriate. Components of an ideal IUS disease activity index were identified based upon panel discussions. CONCLUSIONS: The panel identified appropriate component items and applications of IUS for CD clinical trials. Empiric evidence, and development and validation of an IUS disease activity index are needed.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Goodsall TM, Jairath V, Feagan BG, et al. Standardisation of intestinal ultrasound scoring in clinical trials for luminal Crohn's disease. Aliment Pharmacol Ther. 2021. PMID: 33641221. doi:10.1111/apt.16288

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。